XTEP Ignites Global Night Running Frenzy: Over 1,000 Runners Chase Summer PBs in "Acceleration" Night-Training Footwear
On night runs, runners wearing the 360X 2.0 'Acceleration' edition represent more than just visual impact—it reflects a mindset. 'Acceleration' isn't just speed; it's a commitment to forward momentum in life. This drive requires resilient support: Research in the British Journal of Sports Medicine shows 40-50% of recreational runners sustain injuries—primarily in feet and lower limbs—where effective cushioning is proven to mitigate impact forces. Addressing this critical need, the 360X 2.0 features a premium midsole foam synergized with a streamlined carbon plate, dispersing impact energy to reduce joint stress and injury risk while maintaining responsive speed. Through this science-backed design, XTEP footwear empowers athletes to safely pursue PBs after work—transforming biomechanical insights into enduring running joy. The brand's 'Make it Different' philosophy thrives here—championing breakthroughs where protective engineering meets human potential.
The dynamic 'Acceleration' colorway extends beyond the 360X 2.0, also revitalizing Xtep's core performance models for specific running goals, including: Designed for elite racing, the 160X series has propelled 95 athletes worldwide to secure 451 marathon victories. Complementing the race-day dominator, the 260X is built for professional-level training, helping runners break through plateaus and sustain long-term progress. These performance-driven models became the engine of our global XRC night run series, powering over 1,000 runners as they illuminated cityscapes worldwide, their strides tracing landmarks from Malaysia to Vietnam, Norway, and beyond.
From daily runs to race-day goals, Xtep's performance ecosystem delivers tiered solutions for every runner. The 'Acceleration' ethos embodies the relentless pursuit of progress—now amplified through the global Xtep Running Club (XRC). We invite runners worldwide to join XRC: unlock exclusive access to dynamic pop-up runs in iconic cities, where community and cutting-edge gear converge.
About XTEP
XTEP Group, one of the leading sports brands in China, was founded in 1987 and officially established as the brand XTEP in 2001. The Group was listed on the Hong Kong Stock Exchange on June 3, 2008 (01368.hk). In 2019, the Group launched its global strategy, incorporating Saucony, Merrell, K•SWISS, and Palladium to become a leading international sports group with multiple sports brands. For more about XTEP, please visit https://www.globalxtep.com/
View original content to download multimedia: https://www.prnewswire.com/apac/news-releases/xtep-ignites-global-night-running-frenzy-over-1-000-runners-chase-summer-pbs-in-acceleration-night-training-footwear-302498227.html
SOURCE Xtep
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Apple Inc. (AAPL): People Are Tired Of The Stock Buybacks, Says Jim Cramer
We recently published . Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer recently discussed. Cramer continues to be one of Apple Inc. (NASDAQ:AAPL)'s strongest proponents even though the firm's shares have lost 12.6% year-to-date. The stock has struggled due to trade tensions between the US and China that have threatened to disrupt the supply chain, the firm's struggle to convince the market about its presence in the AI market, and concerns about slow iPhone sales. However, the CNBC host believes that Apple Inc. (NASDAQ:AAPL) will maintain its stature as long as the firm holds its high-end smartphone market share. This time around, he criticized Apple Inc. (NASDAQ:AAPL)'s stock buybacks and deemed them inadequate: '[On reports of Apple reportedly looking to rely on third party AI] Look at how the stock reacted. Because people are tired of Apple just saying, you know what we're gonna do, we're gonna buy back stock until we get something better. No. I mean that's not what you can do anymore. A wide view of an Apple store, showing the range of products the company offers. Cramer commented on Apple Inc. (NASDAQ:AAPL)'s woes in detail recently. Here is what he said: '. . .Apple, which cannot get out of its own way. And I think probably could go down to 25 times earnings. Which is a substantial decline. Apple's a share donor. It's a share donor. '[On why Apple stock should be bought] No I'm not going to because I think the multiple's too high. While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Sustainable Momentum Drove Sea Limited's (SE) Performance in Q2
Lakehouse Capital, a Sydney-based investment manager, released its 'Lakehouse Global Growth Fund' May 2025 investor letter. A copy of the letter can be downloaded here. May proved to be a favorable month for the Fund, driven by a boost in investor sentiment and solid results from portfolio holdings. Overall, the firm remains satisfied with the strong fundamental performance and long-term growth outlook of its portfolio holdings. The Fund returned 6.1% net of fees and expenses for the month compared to 5.1% for its benchmark. Since its inception in December 2017, the Fund has returned 250.6% compared to 133.8% for its benchmark, the MSCI All Country World Index, Net Total Returns (AUD). In addition, please check the fund's top five holdings to know its best picks in 2025. In its May 2025 investor letter, Lakehouse Global Growth Fund highlighted stocks such as Sea Limited (NYSE:SE). Headquartered in Singapore, Sea Limited (NYSE:SE) is a consumer internet company that operates through E-commerce, Digital financial services, and Digital entertainment segments. The one-month return of Sea Limited (NYSE:SE) was -12.28%, and its shares gained 109.08% of their value over the last 52 weeks. On July 3, 2025, Sea Limited (NYSE:SE) stock closed at $149.47 per share, with a market capitalization of $88.489 billion. Lakehouse Global Growth Fund stated the following regarding Sea Limited (NYSE:SE) in its May 2025 investor letter: "Sea Limited (NYSE:SE) delivered another impressive result, with sustained momentum driving solid top-line growth and continued progress on profitability. Group revenue grew 30% to US$4.8 billion, driven by strong performance from the company's e-commerce platform, Shopee, and its fintech business, Monee. Shopee further extended its market leadership across Asia and Brazil, with record GMV rising 22% to US$28.6 billion and continued improvement in its take rate, up 60 basis points to 12.3%. Monee accelerated its growth with their loan book rising 77% to US$5.8 billion, driven by a >50% increase in active borrowers to over 28 million whilst maintaining sound credit quality. Combined with strong operating leverage across all business units, this growth helped lift adjusted EBITDA 136% to US$947 million and continues to demonstrate Sea's ability to deliver further profitable growth." A person livestreaming their gameplay on a mobile device with integrated payment options. Sea Limited (NYSE:SE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 84 hedge fund portfolios held Sea Limited (NYSE:SE) at the end of the first quarter compared to 86 in the previous quarter. Sea Limited's (NYSE:SE) total revenue increased 30% year-on-year to $4.8 billion in the first quarter of 2025. While we acknowledge the potential of Sea Limited (NYSE:SE) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Sea Limited (NYSE:SE) and shared Sands Capital Technology Innovators Fund's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of SE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Soaring Stocks With More Upside Potential to Buy and Hold
Summit Therapeutics' potential pipeline could help drive strong stock performances for a long time. SoFi is finally showing that its business model can be profitable, and the stock still has plenty of upside. 10 stocks we like better than Summit Therapeutics › Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others still boast significant upside potential after juicy gains. It's best to stay away from the former, but the investing wisdom according to which we should "buy low" still applies to the latter. Let's consider two companies that have performed exceptionally well recently but still have excellent long-term prospects: Summit Therapeutics (NASDAQ: SMMT) and SoFi Technologies (NASDAQ: SOFI). Summit Therapeutics has been on a tear over the past two years thanks to progress with its leading pipeline candidate, ivonescimab. The biotech licensed out this investigational cancer medicine from China-based Akeso Biopharma. Summit Therapeutics owns the rights to the medicine in most regions, including the most lucrative ones for biotech companies: North America and Europe. Last year, ivonescimab produced excellent results in a phase 3 study in China (where it is approved) for patients with non-small cell lung cancer (NSCLC). The study pitted ivonescimab against the market leader, Merck's Keytruda. Since Keytruda is the world's best-selling drug and NSCLC is one of its most important markets, ivonescimab's potential looks massive. Although Summit Therapeutics' shares have already soared as a result, the company's future still looks bright. Here are two reasons why. First, Summit Therapeutics is conducting late-stage studies for ivonescimab in the U.S. and is expected to release key data readouts in the next couple of years, which could significantly affect its stock price. Second, even though NSCLC is going to be a crucial market for ivonescimab's success, the medicine looks like a potential pipeline in a drug. It is being tested across many different types of cancers. Ivonescimab could rack up approvals and label expansions for years to come. Summit may encounter clinical or regulatory setbacks. It's good to keep that in mind before initiating a position. But the stock could deliver monster results in the next five years if its master plan comes to fruition. Shares of SoFi -- an online bank -- have more than doubled over the trailing 12-month period. That's an impressive achievement, especially considering the somewhat challenging economic conditions we face. Many fear that President Donald Trump's trade agenda could lead to inflation or a recession. That would affect consumer behavior, resulting in slower loan demand and increased loan defaults, all of which would be detrimental to SoFi. Despite the risk, the market has been impressed with SoFi's financial results. In the first quarter, the company's revenue increased by 20% year over year to $771.8 million. SoFi's net income dropped by 19% year over year to $71.1 million, but it was well above management's own guidance. SoFi's results were strong across the board, with the company's membership and products also moving in the right direction. That will remain the blueprint for long-term success for SoFi. First, the number of members on its platform should continue growing. SoFi is an entirely online bank with no physical locations (which allows the company to save on overhead costs). Digital banking is the future, as evidenced by the fact that younger generations are more likely to engage in it than older ones. Legacy banking institutions have adapted, but SoFi is also popular -- it ended Q1 with a record 10.9 million members, up 34% compared to the year-ago period. Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its existing users. The company recorded 15.9 million products in Q1. That means it had, on average, about 1.5 products per member, despite offering many more than that amount. Third, SoFi has consistently expanded its pool of offerings, which provides other growth opportunities and makes its platform even more attractive to consumers. Although the stock could suffer in a recession, SoFi is well-positioned to perform well over the long run. So, even after its terrific performance in the past year, the stock remains a buy. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy. 2 Soaring Stocks With More Upside Potential to Buy and Hold was originally published by The Motley Fool
